Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 30

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 30
---
2024Interest expense$739 $720 $2,179 $2,106 Interest income(72)(129)(207)(556)Interest expense, net$667 $591 $1,972 $1,550 

Inventories(in millions)September 30,2025December 31, 2024Finished goods$1,579 $1,173 Work-in-process2,277 1,951 Raw materials1,082 1,057 Inventories$4,938 $4,181 

2025 Form 10-Q | 6

Property and Equipment, Net(in millions)September 30,2025December 31, 2024Property and equipment, gross$13,229 $12,267 Accumulated depreciation(7,746)(7,133)Property and equipment, net$5,483 $5,134 Depreciation expense was $192 million for the three months and $559 million for the nine months ended September 30, 2025 and $191 million for the three months and $558 million for the nine months ended September 30, 2024.

Note 3 Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.

The following table summarizes the impact of the two-class method:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions, except per share data)2025202420252024Basic EPSNet earnings attributable to AbbVie Inc.$186 $1,561 $2,410 $4,300 Earnings allocated to participating securities10 10 30 30 Earnings available to common shareholders$176 $1,551 $2,380 $4,270 Weighted-average basic shares outstanding1,769 1,769 1,769 1,769 Basic earnings per share attributable to AbbVie Inc.$0.10 $0.88 $1.35 $2.41 Diluted EPSNet earnings attributable to AbbVie Inc.$186 $1,561 $2,410 $4,300